<< Back to News

1/12/22 mb Short Course Remdesivir in ADULT Patients
January 13, 2022

From: "Madeline Belk" <madeline.belk@hhsys.org>
To: "grp allpharm" <grp_allpharm@hhsys.org>
Sent: Wednesday, January 12, 2022 12:37:00 PM
Subject: Short Course Remdesivir in ADULT Patients
2021 - Gottlieb - Pinetree

ADULT ONLY APPROVED HH - COVID-19 -Short Course Remdesivir Criteria for ....

Good morning, pharmacists –

New literature recently came out supporting early remdesivir to prevent progression to severe COVID-19 (the PINETREE study, attached FYI). This study showed 87% lower risk of hospitalization or death in patients treated in the outpatient setting. These results are comparable to those of the monoclonal antibodies (i.e. sotrovimab). In light of the monoclonal antibody shortage, remdesivir has been emergently approved by P&T for use in ADULT patients who are hospitalized and incidentally found to be COVID-19 positive.

The duration for patients incidentally found to be COVID-19 positive is shorter than that of remdesivir for patients who are hospitalized for COVID-19 (3 days vs. 5 days, respectively). Please make sure to double check the regimen as there are now two different ways it can be ordered. The possible remdesivir regimens for patients are listed below:

• Hospitalized for COVID-19: remdesivir 200 mg IV x 1 on day 1, remdesivir 100 mg IV q24h on days 2-5 (5-day course)

o   Refer to “Remdesivir – Traditional Course” on FormWeb for inclusion/exclusion criteria

• Incidentally found to be COVID-19 (i.e. not admitted for COVID-19): remdesivir 200 mg IV x 1 on day 1, remdesivir 100 mg IV q24h on days 2 and 3 (3-day course)

o   Refer to “Remdesivir – Short Course” on FormWeb for inclusion/exclusion criteria, also attached to this email

PharmIT has built an order sentence to help direct providers to choose the length of treatment (traditional or short-course) that they would like the patient to receive. AMT has educated the ID physicians on this order change and expect them to use it to help lessen confusion.

At this time, short-course remdesivir has NOT been approved in PEDIATRICS. It will be presented at Peds P&T next week. We will update you after a decision is made in this population.

If you have any questions or need further clarification, please contact AMT or the COVID-19 Hotline (256-469-8560).

Thanks,